Polynucleotides encoding low density lipoprotein receptor

• US 10,323,076 B2
• Filed: 10/03/2014
• Issued: 06/18/2019
• Est. Priority Date: 10/03/2013
• Status: Active Grant

• Current Assignee: Moderna TX, Inc. (Moderna, Inc.)
• Original Assignee: Moderna TX, Inc. (Moderna, Inc.)
• Inventors: Ellsworth, Jeff Lynn, Bolen, Joseph Beene, Gregoire, Francine M., Guild, Justin
• Primary Examiner(s): Gonzalez, Antonio Galisteo
• Application Number:
  US15/026,945
• Publication Number:
  US 20160244501A1
• Time in Patent Office: 1,719 Days
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748

Abstract

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules encoding low density lipoprotein receptor comprising at least one mutation (e.g., an LDLR signally enhancing mutation).

Claims

1. A polynucleotide encoding a variant low density lipoprotein receptor (LDLR) wherein the variant LDLR comprises at least one amino acid substitution in the EGF-A domain which corresponds to the sequence of amino acid 314 to amino acid 353 of SEQ ID NO:

43 and at least two amino acid substitutions in the intracellular domain which corresponds to the sequence of amino acid 811 to amino acid 860 of SEQ ID NO;

43, wherein the polynucleotide comprises;

A. (a) a first region of linked nucleosides encoding a polypeptide comprising the variant LDLR;

B. (b) a first flanking region located 5′

relative to said first region comprising at least one 5′

terminal cap;

C. (c) a second flanking region located 3′

relative to said first region comprising a 3′

tailing sequence of linked nucleosides; and

D. wherein said polynucleotide is a mRNA comprising, at least one chemically modified nucleoside; and

wherein the variant LDLR comprises an amino acid sequence selected from the group consisting of;

SEQ ID NO;

50, SEQ ID NO;

51, SEQ ID NO;

52, SEQ ID NO;

53, SEQ ID NO;

724, SEQ ID NO;

725, SEQ ID NO;

726, and SEQ ID NO;

727; and

/or the variant LDLR comprises an amino acid substitution in the intracellular domain corresponding to amino acid 816 of SEQ ID NO;

43, amino acid 830 of SEQ ID NO;

43, amino acid 839 of SEQ ID NO;

43, or any combination thereof.

2. The polynucleotide of claim 1, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:

50, SEQ ID NO;

51, SEQ ID NO;

52, SEQ ID NO;

53, SEQ ID NO;

724, SEQ ID NO;

725, SEQ ID NO;

726, and SEQ ID NO;

727.

3. The polynucleotide of claim 1, wherein the polypeptide comprises an amino acid sequence selected from SEQ ID NO:

50 or SEQ ID NO;

52.

4. The polynucleotide of claim 1, wherein the mRNA is fully modified.

5. The polynucleotide of claim 1, wherein the polynucleotide is formulated with a lipid nanoparticle.

6. The polynucleotide of claim 1, wherein the variant LDLR has higher expression and longer half-life than wild-type LDLR.

7. The polynucleotide of claim 1, wherein the amino acid substitution in the intracellular domain corresponds to amino acid 816 of SEQ ID NO:

43, amino acid 830 of SEQ ID NO;

43, amino acid 839 of SEQ ID NO;

43, or any combination thereof.

8. The polynucleotide of claim 7, wherein the amino acid substitutions in the intracellular domain is the combination of K830R and C839A.

9. The polynucleotide of claim 1, wherein the amino acid substitution in the EGF-A domain corresponds to amino acid 316 of SEQ ID NO:

43, 339 of SEQ ID NO;

43, or a combination thereof.

10. The polynucleotide of claim 1, wherein the amino acid substitution in the intracellular domain corresponds to amino acid 816 of SEQ ID NO:

43, amino acid 830 of SEQ ID NO;

43, amino acid 839 of SEQ ID NO;

43, or any combination thereof; and

wherein the amino acid substitution in the EGF-A domain corresponds to amino acid 316 of SEQ ID NO;

43, 339 of SEQ ID NO;

43, or a combination thereof.

11. The polynucleotide of claim 10, wherein the amino acid substitution in the EGF-A domain is L339D and the amino acid substitution in the intracellular domain is the combination of K830R and C839A.

12. The polynucleotide of claim 2, wherein the mRNA is fully modified.

13. The polynucleotide of claim 2, wherein the polynucleotide is formulated with a lipid nanoparticle.